164 related articles for article (PubMed ID: 35537661)
1. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer.
Levink IJM; Visser IJ; Koopmann BDM; van Driel LMJW; Poley JW; Cahen DL; Bruno MJ; Fuhler GM
Gastrointest Endosc; 2022 Nov; 96(5):801-813.e2. PubMed ID: 35537661
[TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
[TBL] [Abstract][Full Text] [Related]
3. Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma.
Nesteruk K; Levink IJM; Dits NFJ; Cahen DL; Peppelenbosch MP; Bruno MJ; Fuhler GM
Clin Transl Gastroenterol; 2022 Feb; 13(3):e00465. PubMed ID: 35363220
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas.
Kaur S; Baine MJ; Guha S; Ochi N; Chakraborty S; Mallya K; Thomas C; Crook J; Wallace MB; Woodward TA; Jain M; Singh S; Sasson AR; Skinner V; Raimondo M; Batra SK
Pancreas; 2013 Apr; 42(3):494-501. PubMed ID: 23146921
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
6. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
7. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
8. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
[TBL] [Abstract][Full Text] [Related]
10. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
11. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
13. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
14. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
16. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer.
Tanaka H; Tamura K; Abe T; Yoshida T; Macgregor-Das A; Dbouk M; Blackford AL; Borges M; Lennon AM; He J; Burkhart R; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2267-2275.e2. PubMed ID: 34648951
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
[TBL] [Abstract][Full Text] [Related]
18. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
[TBL] [Abstract][Full Text] [Related]
19. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]